Ozempic superior in lowering blood sugar and weight vs placebo

4 March 2019

Danish diabetes care giant Novo Nordisk (NOV: N) has today announced the publication of positive results from the SUSTAIN 9 Phase IIIb trial in The Lancet Diabetes & Endocrinology.

The objective of this 30 week trial was to assess the efficacy and safety of Ozempic(semaglutide) 1.0mg when added to SGLT-2 inhibitor (SGLT-2i) therapy.In SUSTAIN 9, adults with type 2 diabetes were randomized to receive once-weekly semaglutide or placebo in addition to an SGLT-2i, either as monotherapy or in combination with metformin or sulfonylurea. 1

The trial met its primary endpoint, with Ozempic injection 1.0mg demonstrating a statistically-significant and superior reduction in HbA1c of 1.5% versus 0.1% with placebo, both in combination with SGLT2-i treatment, from an overall mean baseline of 8.0%. Additional findings of a secondary endpoint showed that Ozempic 1.0mg demonstrated a statistically-significant and superior reduction in body weight of 4.7kg vs 0.9kg with placebo, from an overall mean baseline of 91.7kg. 1

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK